Laddar…
Academic Journal
COST-UTILITY ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS
R. I. Yagudina, A. Yu. Kulikov, I. A. Komarov
Фармакоэкономика, Vol 6, Iss 3, Pp 10-16 (2015)
Sparad:
| Titel | COST-UTILITY ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS |
|---|---|
| Författarna | R. I. Yagudina, A. Yu. Kulikov, I. A. Komarov |
| Utgivningsår |
2015
|
| Källa |
Фармакоэкономика, Vol 6, Iss 3, Pp 10-16 (2015)
|
| Beskrivning |
Chronic myeloid leukemia (CML) accounts for roughly 20% of leucosis in adults, and this pathology incidence is about 1-2 cases on 100 000 men annually. Pharmacoeconomic evaluation of this pathology contributes to the improvement of approaches to treatment policy of this group of patients. We performed cost-effectiveness analysis and cost-utility analysis on the basis of two tyrosine kinase inhibitors in Russian Federation – nilotinib (Tasigna) and imatinib (Gleevec) in CML in the chronic phase (CP) treatment as first-line therapy. Treatment with Tasigna compared with Gleevec characterizes as dominant or acceptable according to used time horizons.
|
| Dokumenttyp |
article
|
| Språk |
Russian
|
| Information om utgivare |
IRBIS LLC, 2015.
|
| Ämnestermer |
фармакоэкономический анализ, хронический миелолейкоз, терапия первой линии, ингибиторы тирозинкиназы, нилотиниб, тасигна, иматиниб, гливек, анализ «затраты- эффективность», анализ «затраты-полезность», оценка технологий здравоохранения, Therapeutics. Pharmacology, RM1-950, Economics as a science, HB71-74
|
